Clinical Trial Update: Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating apixaban to reduce thrombo-embolism in patients with device-detected subclinical atrial fibrillation; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Stroke

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Population Health Research Institute | Conditions: Atrial Fibrillation, Stroke | Phase 4 | Status: COMPLETED